RSA
REGN icon

River Street Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

River Street Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-615
Closed -$390K – 169
2025
Q1 		$390K Buy
615
+62
+11% +$42.6K 0.19% 105
2024
Q4 		$394K Buy
553
+41
+8% +$34.4K 0.2% 104
2024
Q3 		$538K Buy
512
+8
+2% +$8.9K 0.29% 87
2024
Q2 		$530K Buy
504
+44
+10% +$42.7K 0.33% 86
2024
Q1 		$443K Buy
460
+30
+7% +$28.5K 0.3% 87
2023
Q4 		$378K Sell
430
-57
-12% -$46.9K 0.3% 83
2023
Q3 		$401K Buy
487
+22
+5% +$17.3K 0.38% 80
2023
Q2 		$334K Sell
465
-9
-2% -$6.94K 0.32% 86
2023
Q1 		$389K Buy
474
+14
+3% +$10.6K 0.38% 79
2022
Q4 		$332K Buy
+460
New +$339K 0.36% 82

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

River Street Advisors's REGN Position: Q2 2025 in Review

River Street Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 615 shares — an estimated $390K sold.

River Street Advisors first reported a position in REGN in Q4 2022 and held it in 10 quarters. The position peaked at $538K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • River Street Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • River Street Advisors sold 615 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $390K.
  • River Street Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • River Street Advisors's Regeneron Pharmaceuticals position peaked at $538K in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on River Street Advisors's 13F filing for Q2 2025, filed 21 Jul 2025.